Nicotine has long been at the center of debates surrounding smoking and its associated health risks. However, widespread misinformation—or disinformation, as it is often deliberately designed to confuse the public and consumers—continues to obscure the facts about nicotine’s actual role in tobacco-related diseases. By addressing these myths and focusing on evidence-based knowledge, we can improve…
1. Executive Summary Safer nicotine products (SNPs), such as nicotine pouches, lozenges, gums, dissolvables and other reduced-risk nicotine alternatives, should not be regulated in the same manner as combustible smoking tobacco products and nicotine vaping products because they– • are smokeless and do not pose the same relative health risks; • readily contribute to a…
As the global conversation on tobacco harm reduction evolves, regulatory frameworks for novel nicotine products are under scrutiny. Broughton Life Sciences Ltd., a leading consultancy in life sciences, recently submitted comprehensive recommendations to the UK Parliament, offering a roadmap for establishing safety, quality, and compliance standards for nicotine pouches and other reduced-risk alternatives. Key Recommendations…
As nicotine products evolve, public health policies must adapt to reflect scientific evidence and advance harm reduction goals. Central to this evolution is the idea of risk-proportionate taxation—a fiscal framework that aligns tax rates with the relative health risks of different nicotine products. This approach not only supports harm reduction but also incentivizes smokers to…
As the U.K. Parliament advances the Tobacco and Vapes Bill, a key feature is the introduction of a licensing scheme for retailers of nicotine pouches and alternative nicotine products. This initiative aims to regulate sales and storage, ensuring public health and safety. What Retailers Need to Know 🔹 Dual Licensing Requirement: Retailers must obtain both…
As the UK Tobacco and Vapes Bill advances in the House of Commons, GINN is preparing to contribute its insights. We believe the regulatory framework must balance innovation with public health while ensuring consumer safety. Here’s what we propose: 🔹 Market Access: Introduce a clear and transparent notification process for manufacturers, requiring detailed disclosures of…
As the European Union considers new tax measures under the proposed revision of the Tobacco Excise Directive (TED), the focus on nicotine pouches highlights the growing debate over their regulation and taxation. This burgeoning segment within the nicotine market holds promise for harm reduction, but significant taxation could undermine its potential to encourage smokers to…
Nicotine and tobacco products exist on a spectrum of risk, ranging from the highest to the lowest health impact. This risk continuum provides a valuable framework for understanding the varying health effects of these products on individuals and populations, empowering people to make more informed decisions for their health. The High-Risk End: Combustible Tobacco Products…
Greece has emerged as a leader in innovative strategies to reduce smoking-related harm, reflecting its commitment to improving public health. Over the past few years, the country has introduced comprehensive measures to combat smoking while embracing harm reduction as a pivotal part of its national strategy. The National Action Plan Against Smoking In November 2019,…
Nicotine, widely known for its association with tobacco products, is also recognized as an approved drug by health authorities such as the World Health Organization (WHO). In therapeutic contexts, nicotine plays a pivotal role in smoking cessation strategies, offering safer alternatives to combustible tobacco use. When delivered without the harmful effects of combustion, nicotine replacement…